Addex FY25 net loss widens to CHF 6.7 million; cash falls to CHF 1.6 million

• Addex posted a net loss of CHF 6.73 million in 2025, swinging from a prior-year profit as discontinued-operations profit fell to CHF 114,000.
• Revenue declined 57.8% to CHF 173,000 due to completion of the research phase of its Indivior collaboration on June 30, 2024.
• Operating loss widened to CHF 2.82 million as G&A held at CHF 2.32 million despite R&D easing to CHF 672,000.
• Cash slipped to CHF 1.64 million at year-end from a CHF 1.7 million net cash decrease during the year, while shareholders’ equity fell to CHF 4.77 million.
• Operationally, Addex advanced its GABAB PAM chronic cough candidate toward the clinic and continued repositioning dipraglurant for brain injury recovery, with CEO Tim Dyer citing “robust and sustained progress” and no financial outlook provided.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Addex Therapeutics Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202604300100OMX_____CNEWS_EN_GNW1001178958_en) on April 30, 2026, and is solely responsible for the information contained therein.